{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:27:42Z","timestamp":1779895662117,"version":"3.53.1"},"reference-count":50,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5,1]]},"abstract":"<jats:sec>\n                  <jats:title>BACKGROUND:<\/jats:title>\n                  <jats:p>Polycystic ovarian syndrome (PCOS) is a common disease. There is limited evidence to support various treatment choices. This leads to variable treatment practices.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>OBJECTIVES:<\/jats:title>\n                  <jats:p>To conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the use of metformin versus oral contraceptive pills (OCPs) for the treatment of PCOS in adolescents aged 11 to 19 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>DATA SOURCES:<\/jats:title>\n                  <jats:p>We performed literature searches through Ovid Medline, Ovid Embase, Cochrane Central Register of Controlled Trials, and gray literature resources, up to January 29, 2015.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>STUDY SELECTION AND DATA EXTRACTION:<\/jats:title>\n                  <jats:p>Two reviewers screened titles and abstracts of identified citations, assessed full text eligibility, and extracted information from eligible trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS:<\/jats:title>\n                  <jats:p>Four RCTs met the inclusion and exclusion criteria. The reviewed evidence came from 170 patients. Overall, OCP treatment resulted in modest improvement in menstrual cycle frequency (weighted mean difference [WMD] = 0.27, P &amp;lt; .01, 95% confidence interval [CI] \u22120.33 to \u22120.21) and mild reduction of acne scores (WMD = 0.3, P = .02, 95% CI 0.05 to 0.55). While metformin resulted in greater BMI reduction (WMD = \u22124.02, P &amp;lt; .01, 95% CI \u22125.23 to \u22122.81) it was associated with decreased dysglycemia prevalence (risk ratio: 0.41, P = .02, 95% CI 0.19 to 0.86) and improved total cholesterol and low-density lipoprotein levels. Metformin and OCPs were similar in terms of impact on hirsutism.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS AND LIMITATIONS:<\/jats:title>\n                  <jats:p>Current evidence is derived from very low to low quality evidence. Therefore, treatment choice should be guided by patient values and preferences while balancing potential side effects. Future high quality RCTs are needed to address several questions for the treatment of adolescents with PCOS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2015-4089","type":"journal-article","created":{"date-parts":[[2016,4,28]],"date-time":"2016-04-28T12:12:23Z","timestamp":1461845543000},"source":"Crossref","is-referenced-by-count":75,"title":["Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis"],"prefix":"10.1542","volume":"137","author":[{"given":"Reem A.","family":"Al Khalifah","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Pediatrics,"},{"name":"Departments of Clinical Epidemiology and Biostatistics,"},{"name":"Department of Pediatrics, King Saud University, Riyadh, Saudi Arabia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan D.","family":"Florez","sequence":"additional","affiliation":[{"name":"Departments of Clinical Epidemiology and Biostatistics,"},{"name":"Department of Pediatrics, Universidad de Antioquia, Colombia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Dennis","sequence":"additional","affiliation":[{"name":"Departments of Clinical Epidemiology and Biostatistics,"},{"name":"St. George\u2019s University of London, Cranmer Terrace, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lehana","family":"Thabane","sequence":"additional","affiliation":[{"name":"Departments of Clinical Epidemiology and Biostatistics,"},{"name":"Pediatrics and Anesthesia, McMaster University, Hamilton, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ereny","family":"Bassilious","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Pediatrics,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2016,5,1]]},"reference":[{"issue":"9","key":"2021120904332513400_B1","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1093\/humrep\/det262","article-title":"Prevalence of polycystic ovary syndrome in women in China: a large community-based study.","volume":"28","author":"Li","year":"2013","journal-title":"Hum Reprod"},{"issue":"2","key":"2021120904332513400_B2","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.fertnstert.2013.04.001","article-title":"Prevalence of polycystic ovary syndrome in adolescents.","volume":"100","author":"Christensen","year":"2013","journal-title":"Fertil Steril"},{"issue":"10","key":"2021120904332513400_B3","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1093\/humrep\/des232","article-title":"Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria.","volume":"27","author":"Yildiz","year":"2012","journal-title":"Hum Reprod"},{"issue":"12","key":"2021120904332513400_B4","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1210\/jc.2013-2350","article-title":"Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.","volume":"98","author":"Legro","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2021120904332513400_B5","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1056\/NEJMra041536","article-title":"Polycystic ovary syndrome.","volume":"352","author":"Ehrmann","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"2021120904332513400_B6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrendo.2010.217","article-title":"Polycystic ovary syndrome: etiology, pathogenesis and diagnosis.","volume":"7","author":"Goodarzi","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"2021120904332513400_B7","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1111\/j.1464-5491.2011.03460.x","article-title":"Current perspectives of insulin resistance and polycystic ovary syndrome.","volume":"28","author":"Pauli","year":"2011","journal-title":"Diabet Med"},{"issue":"6","key":"2021120904332513400_B8","first-page":"774","article-title":"Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.","volume":"18","author":"Dunaif","year":"1997","journal-title":"Endocr Rev"},{"issue":"6","key":"2021120904332513400_B9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1590\/S0100-72032013000600003","article-title":"[Clinical manifestations, biochemical, ultrasonographic and metabolic of polycystic ovary syndrome in adolescents].","volume":"35","author":"Rehme","year":"2013","journal-title":"Rev Bras Ginecol Obstet"},{"issue":"6","key":"2021120904332513400_B10","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jpag.2012.07.006","article-title":"Clinical and metabolic features of polycystic ovary syndrome among Chinese adolescents.","volume":"25","author":"Li","year":"2012","journal-title":"J Pediatr Adolesc Gynecol"},{"issue":"1","key":"2021120904332513400_B11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jpag.2009.04.004","article-title":"Characteristics of adolescents presenting to a multidisciplinary clinic for polycystic ovarian syndrome.","volume":"23","author":"Bekx","year":"2010","journal-title":"J Pediatr Adolesc Gynecol"},{"issue":"1","key":"2021120904332513400_B12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jadohealth.2013.12.020","article-title":"Diagnosing dysglycemia in adolescents with polycystic ovary syndrome.","volume":"55","author":"Gooding","year":"2014","journal-title":"J Adolesc Health"},{"issue":"1","key":"2021120904332513400_B13","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1399-5448.2012.00902.x","article-title":"Polycystic ovary syndrome in adolescence: impaired glucose tolerance occurs across the spectrum of BMI.","volume":"14","author":"Flannery","year":"2013","journal-title":"Pediatr Diabetes"},{"issue":"3","key":"2021120904332513400_B14","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1210\/jcem.87.3.8305","article-title":"Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome.","volume":"87","author":"Palmert","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2021120904332513400_B15","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/cen.12068","article-title":"Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study.","volume":"78","author":"Mani","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2021120904332513400_B16","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1210\/jc.2014-3886","article-title":"The potential implications of a PCOS diagnosis on a woman\u2019s long-term health using data linkage.","volume":"100","author":"Hart","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2021120904332513400_B17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/humupd\/dml036","article-title":"A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome.","volume":"12","author":"Boomsma","year":"2006","journal-title":"Hum Reprod Update"},{"issue":"5","key":"2021120904332513400_B18","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/humupd\/dmu012","article-title":"Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis.","volume":"20","author":"Barry","year":"2014","journal-title":"Hum Reprod Update"},{"issue":"1","key":"2021120904332513400_B19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1634\/theoncologist.2014-0311","article-title":"A nationwide population-based retrospective cohort study of the risk of uterine, ovarian and breast cancer in women with polycystic ovary syndrome.","volume":"20","author":"Shen","year":"2015","journal-title":"Oncologist"},{"issue":"1","key":"2021120904332513400_B20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ygyno.2014.11.012","article-title":"Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study.","volume":"136","author":"Gottschau","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"(5","key":"2021120904332513400_B21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1552-6909.2011.01279.x","article-title":"Health-related quality of life among adolescents with polycystic ovary syndrome.","volume":"40","author":"Jones","year":"2011","journal-title":"J Obstet Gynecol Neonatal Nurs"},{"issue":"4","key":"2021120904332513400_B22","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/0898010111398660","article-title":"Managing polycystic ovary syndrome: what our patients are telling us","volume":"29","author":"Crete","year":"2011","journal-title":"J Holist Nurs"},{"issue":"2","key":"2021120904332513400_B23","doi-asserted-by":"crossref","first-page":"e13612","DOI":"10.5812\/ijem.13612","article-title":"The experience of women affected by polycystic ovary syndrome: a qualitative study from Iran.","volume":"12","author":"Nasiri Amiri","year":"2014","journal-title":"Int J Endocrinol Metab"},{"issue":"4","key":"2021120904332513400_B24","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jpag.2013.03.007","article-title":"Differences in the management of adolescents with polycystic ovary syndrome across pediatric specialties.","volume":"26","author":"Auble","year":"2013","journal-title":"J Pediatr Adolesc Gynecol"},{"issue":"4","key":"2021120904332513400_B25","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1530\/EJE-14-0252","article-title":"European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest Group\u2019s Questionnaire.","volume":"171","author":"Conway","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2021120904332513400_B26","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jpag.2013.03.007","article-title":"Differences in the management of adolescents with polycystic ovary syndrome across pediatric specialties.","volume":"26","author":"Auble","year":"2013","journal-title":"J Pediatr Adolesc Gynecol"},{"issue":"7","key":"2021120904332513400_B27","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"9","key":"2021120904332513400_B28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/pch\/8.9.577","article-title":"Age limits and adolescents.","volume":"8","year":"2003","journal-title":"Paediatr Child Health"},{"issue":"2","key":"2021120904332513400_B29","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.fertnstert.2008.06.035","article-title":"The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.","volume":"91","author":"Azziz","year":"2009","journal-title":"Fertil Steril"},{"key":"2021120904332513400_B30","first-page":"377","article-title":"Diagnostic criteria for polycystic ovary syndrome: towards a rational approach","volume-title":"Polycystic Ovary Syndrome","author":"Zawadski","year":"1992","edition":"1st ed."},{"issue":"5","key":"2021120904332513400_B31","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2002-021528","article-title":"A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills.","volume":"88","author":"Diamanti-Kandarakis","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2021120904332513400_B32","unstructured":"McMaster University. Search Filters for MEDLINE in Ovid Syntax and the PubMed translation. Available at: http:\/\/hiru.mcmaster.ca\/hiru\/HIRU_Hedges_MEDLINE_Strategies.aspx. Accessed March 2, 2016"},{"key":"2021120904332513400_B33","author":"Higgins"},{"issue":"2","key":"2021120904332513400_B34","first-page":"45","article-title":"The diagnosis of polycystic ovary syndrome in adolescents.","volume":"4","author":"Roe","year":"2011","journal-title":"Rev Obstet Gynecol"},{"issue":"2","key":"2021120904332513400_B35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.contraception.2010.02.009","article-title":"Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.","volume":"82","author":"Kriplani","year":"2010","journal-title":"Contraception"},{"issue":"3","key":"2021120904332513400_B36","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jclinepi.2011.04.015","article-title":"Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid.","volume":"65","author":"Akl","year":"2012","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"2021120904332513400_B37","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables.","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"2021120904332513400_B38","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jclinepi.2011.04.014","article-title":"GRADE guidelines: 8. Rating the quality of evidence--indirectness.","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"2021120904332513400_B39","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1515\/JPEM.2005.18.8.761","article-title":"Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome.","volume":"18","author":"Allen","year":"2005","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"11","key":"2021120904332513400_B40","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1210\/jc.2008-0461","article-title":"The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials.","volume":"93","author":"Hoeger","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"7-8","key":"2021120904332513400_B41","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1515\/jpem-2014-0283","article-title":"Randomized clinical trial evaluating metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome.","volume":"28","author":"Al-Zubeidi","year":"2015","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"3","key":"2021120904332513400_B42","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.mefs.2014.10.003","article-title":"A randomized controlled trial of the effects of metformin versus combined oral contraceptives in adolescent PCOS women through a 24 months follow up period.","volume":"20","author":"El Maghraby","year":"2015","journal-title":"Middle East Fertil Soc J"},{"key":"2021120904332513400_B43","article-title":"Randomized Clinical Trial Evaluating Metformin Versus Oral Contraceptive Pills in the Treatment of Adolescents with Polycystic Ovarian Syndrome.","author":"Al-Zubeidi","year":"2014"},{"issue":"11","key":"2021120904332513400_B44","first-page":"CD009038","article-title":"Quadriphasic versus monophasic oral contraceptives for contraception.","author":"Van Vliet","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"2021120904332513400_B45","first-page":"CD003553","article-title":"Triphasic versus monophasic oral contraceptives for contraception.","author":"Van Vliet","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2021120904332513400_B46","first-page":"264","article-title":"Efficacy and bleeding profile of a combined oral contraceptive containing oestradiol valerate\/dienogest: a pooled analysis of three studies conducted in North America and Europe.","author":"Nelson","year":"2013"},{"issue":"8","key":"2021120904332513400_B47","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2165\/11590260-000000000-00000","article-title":"Cycle control and bleeding pattern of a 24\/4 regimen of drospirenone 3 mg\/ethinyl estradiol 20 \u03bcg compared with a 21\/7 regimen of desogestrel 150 \u03bcg\/ethinyl estradiol 20 \u03bcg: a pooled analysis.","volume":"31","author":"Anttila","year":"2011","journal-title":"Clin Drug Investig"},{"issue":"1","key":"2021120904332513400_B48","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-116-1-78","article-title":"A consumer\u2019s guide to subgroup analyses.","volume":"116","author":"Oxman","year":"1992","journal-title":"Ann Intern Med"},{"issue":"1","key":"2021120904332513400_B49","first-page":"CD005552","article-title":"Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome.","author":"Costello","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"2021120904332513400_B50","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1177\/1933719111430993","article-title":"Endometrial abnormality in women with polycystic ovary syndrome.","volume":"19","author":"Shang","year":"2012","journal-title":"Reprod Sci"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2015-4089\/1060867\/peds_20154089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2015-4089\/1060867\/peds_20154089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T21:28:09Z","timestamp":1639085289000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/137\/5\/e20154089\/51995\/Metformin-or-Oral-Contraceptives-for-Adolescents"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,1]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5,1]]},"published-print":{"date-parts":[[2016,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2015-4089","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,1]]},"article-number":"e20154089"}}